Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 15/20 | 0.77 |
| ▸ | CA12 | O43570 | 1/20 | 0.72 |
| ▸ | CA2 | P00918 | 1/20 | 0.72 |
| ▸ | CA9 | Q16790 | 1/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | PKM | P14618 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7092896 | 1.00 | ALDH1A1 (0.77) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL7095731 | 1.00 | ALDH1A1 (0.77) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL7095949 | 1.00 | ALDH1A1 (0.77) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL7095193 | 1.00 | ALDH1A1 (0.77) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL7097551 | 1.00 | ALDH1A1 (0.77) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL7094852 | 0.98 | ALDH1A1 (0.79) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL7201051 | 0.94 | ALDH1A1 (0.86) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL7103280 | 0.93 | ALDH1A1 (0.72) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL634183 | 0.93 | ALDH1A1 (0.72) | ALDH1A1CA12CA2CA9ALOX15 | |
| SCHEMBL8355315 | 0.93 | ALDH1A1 (0.72) | ALDH1A1CA12CA2CA9ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420626-B2 | Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2013-04-16 | — | — | US | disclosed |
| US-20100179116-A1 | Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2010-07-15 | — | — | US | disclosed |
| US-6627399-B1 | Using compound of given formula as accelerator | RIKEN (JP) | 2003-09-30 | — | — | US | disclosed |
| US-6605645-B2 | Such as 1,15-di(cyclopropylmethylamino)-8-benzyl-4,8,12-triazapentadecane; carcinostatic action | RIKEN (JP) | 2003-08-12 | — | — | US | disclosed |
| US-20030073202-A1 | RNA polymerase transcription promoter and nucleic acid sequencing method | IWATA MASAAKI (JP) | 2003-04-17 | — | — | US | disclosed |
| US-20020067472-A1 | Linear polyamine compounds and polyamine anticancer agents | IWATA MASAAKI (JP) | 2002-06-06 | — | — | US | disclosed |
| US-6319956-B1 | N1, N4-BIS(CYCLOPROPYLMETHYLAMINO)TRIALKYLENETETRAMINES THAT MAY BE TOLUENESULFONATED. | RIKEN (JP) | 2001-11-20 | — | — | US | disclosed |
| EP-1061130-A1 | RNA POLYMERASE TRANSCRIPTION PROMOTERS AND METHOD FOR DETERMINING BASE SEQUENCE | Riken (JP) | 2000-12-20 | — | — | EP | disclosed |
| EP-0497202-B1 | Polyamine thiols as radioprotective agents | MERRELL DOW PHARMA (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0495450-B1 | Polyamine phenols as radioprotective agents | MERRELL DOW PHARMA (US) | 1995-07-26 | — | — | EP | disclosed |
| EP-0662829-A1 | POLYAMINE DERIVATIVES AS ANTI-CYTOMEGALOVIRAL AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-07-19 | — | — | EP | disclosed |
| US-5354782-A | Polyamine phenols as radioprotective agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-10-11 | — | — | US | disclosed |
| WO-1994007480-A1 | POLYAMINE DERIVATIVES AS ANTI-CYTOMEGALOVIRAL AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-04-14 | — | — | WO | disclosed |
| US-5217964-A | POLYAMINE THIOLS AS RADIOPROTECTIVE AGENTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-06-08 | — | — | US | disclosed |
| EP-0497202-A1 | Polyamine thiols as radioprotective agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-08-05 | — | — | EP | disclosed |
| EP-0495450-A2 | Polyamine phenols as radioprotective agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179116-A1 | Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof | SRM, SP1, SMS | ALDH1A1 1826/4885CA12 4689/4885CA2 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.